Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (February 2025)
28 slides from Heramed's investor presentation, Feb 19, 2025
Slide 1: Leading the Digital Transformation of Maternity Care
For personal use only Leading the Digital Transformation of Maternity Care Investor Presentation | February 2025 ASX:HMD Regulatory FDA 510K Approved By: clearance
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HeraMED Limited ('HMD'). All information contained in this presentation (including this notice) ('Information') is confidential. By receiving the forward- looking you are deemed to agree that you will hold the Information in strict confidence, and ke
Slide 3: Problem: Century-old Model of Care
Problem Century - old Model of care For personal use only Maternal mortality Access/inequity of care Affordability of care Workforce shortage & burnout 3
Slide 4: Our Mission
Our Mission Experienced (Mums) For personal use only Redefining How Maternity Care Is Delivered and Experienced Delivered (Physicians) 4
Slide 5: Investment Highlights
Investment Highlights For personal use only In more than 4,000 pregnancies to date, HeraCARE has delivered improved care outcomes, increased productivity & higher revenue per user Maternity care in Defined Business Market Leading Structural Leading crisis globally Models Platform Tailwinds Databank
Slide 6: Overview
Overview HeraMED Limited is an Top 5 Shareholders ASX listed (ASX:HMD) $16m For personal use only 1.286m Foreshore Capital 5.4% global medical data Kyriaco Barber Pty Ltd 2.8% and technology Market capitalisation1 Average daily volume JP Morgan Noms 2.7% company leading the Ratdog Pty Ltd 2.6% digit
Slide 7: Key Leadership Team
Key Leadership Team Anoushka Gungadin Nicole Zappala Managing Director & CEO Head of Customer Success & Head Mom For personal use only A career spans more than 20 years and four Over 15 years of experience in startups, including a continents, an experienced CEO, Finance Executive, decade in health t
Slide 8: Maternity Care Model Challenges
Maternity Care Model Challenges An unchanged care model since 1950's For personal use only Challenges for Doctors Challenges for and Providers Expectant Mothers Dramatic shortage of staff La c k o f p ro xim ity a c c e s s a n d fu n d a m e n ta l s e rvic e s to m a te rn ity c a re La c k o f ti
Slide 9: Maternity Care Model Challenges
Maternity Care Model Challenges Maternity deserts in the US are defined by counties with NO maternity clinic within the Country For personal use only 36 % USA BY THE NUMBERS Of the US is a 'maternity desert'. $111bn spent on maternity care annually Mortality rates are 2x that of other OECD countries
Slide 10: Cost of maternity complications
Cost of maternity complications* Opportunity to reduce costs & improve maternity care and outcomes For personal use only Maternal Mental Health Hypertension Gestational US$18.1b annual cost Diabetes related to mental health US$7.5B annual cost US$4.8b annual conditions (suicide, related to hypertens
Slide 11: HeraCARE Solution
HeraBEAT FHR HeraCARE Solution A New Era of Connected Maternity Care Blood Pressure Health Care Provider For personal use only Weight Companion App Mood RPM Remote Pregnancy Smart Messaging Monitoring Surveys Connected Devices He ra CARE Clo u d Pe rs o n a lis e d Ca re Pla n s Glucose Education Ex
Slide 12: HeraCARE: New Era of Connected Maternity Care
HeraCARE: New Era of Connected Maternity Care For personal use only Task based care plans following clinical pathways Low Risk High Risk HDP GDM Fetal Surveillance Hypertensive disorders of pregnancy Gestational Diabetes Weekly Measurements Twice Daily Measurements Twice Daily Measurements Daily Mea
Slide 13: HeraCARE Stakeholder Benefits
HeraCARE Stakeholder Benefits For personal use only Better Health Increased Increase Revenue Outcomes Productivity Gains Per Pregnancy ● Patient-centric care ● Productivity gains of 33%-46% ● Reimbursement landscape structurally changing ● Continuous support ● Up to 50% less in person visits ● Addit
Slide 14: Commercial traction meets untapped data frontiers
Commercial traction meets untapped data frontiers For personal use only Key Strategic Pregnancies DataBank Hybrid model Customised Care Partners managed by continues to Grow of care plans HeraCARE 10 customers 30- 70% of visits 9 care plans 3,950+ accumulated 440,000+ across US, Aust & done remotely
Slide 15: Pregnant mothers endorsing HeraCARE
HERA @ Pregnant mothers endorsing HeraCARE i ) 87% 4.5 Wa Kk kK I: = = Overall - Satisfaction . ; \ 7 ud 8 Ve Rate J : : 4 ‘ () ; a ’ oo is ; Contributed to s{ow/ q 2 ea P =p). \ © Peace of Mind Preferred the RPM Experience -HERA 8 _MED @ a
Slide 16: Four-Point Strategic Plan
Four-Point Strategic Plan For personal use only 1 Commercialisation 2 Strategic 3 Non-Dilutive 4 Brand Focus – Customer First Partnerships Funding / Grants Visibility Focus on near term Partner with industry Pursue non- Create a women’s contracts where and research institutions dilutive funding heal
Slide 17: Our stakeholders
Our stakeholders Government Ke y v e rt ic a ls , m a rk e t s & For personal use only s t ra t e g ic p a rt n e rs h ip s Commercial Health Insurers/ Partners Employers Hospitals and Clinics Care Management Service Providers Midwife-led Research Institutes Maternity Groups & Universities 17
Slide 18: Key Customer – Broward Health
Key Customer – Broward Health Commercial Agreement Terms For personal use only • 2-year agreement for HeraCARE platform and HeraBEAT devices in Broward Health service Broward – a top-10 USA • 700 HeraCARE licences & 200 hardware bundles Public Health Provider • US$200k upfront, with US$400k over 2-y
Slide 19: HeraCARE value proposition being built at Broward
HeraCARE value proposition being built at Broward Mother User MUMS using Data As An Customised Next Steps Satisfaction HeraCARE Asset Care plans For personal use only Mothers surveyed ~400 31,000+ 9 care plans 1. Hybrid care 4.6 /5 accumulated Data now established with model : 30- customers includin
Slide 20: Early channel partners - US & EU
Early channel partners - US & EU • Significant reimbursement programs now available for expanded Metronomics Inc postpartum care programs (specifically mental health monitoring) For personal use only Building a post partum • HMD and Metronomic intend to integrate HeraCARE postpartum care care soluti
Slide 21: On the path to adoption in Australia
On the path to adoption in Australia • This strategic partnership aims to change the models of care and wellbeing for women and babies, including through knowledge University generation, exchange, translation, and impact For personal use only Technology Sydney • INSIGHT is UTS’s Research Institute f
Slide 22: Planned Commercial Model
Planned Commercial Model Reimbursement In The US Allows Healthcare Providers Pricing Model Example To Receive Additional Revenue Per Pregnancy For personal use only Reimbursement Per Pregnancy Private clinic Per Pregnancy 99453 ~$19 One Time $19 ~US$600 99454 ~$62 Avg. 5-month usage $310 OR 99457 ~$
Slide 23: Future of Maternity Care - Pregnancy + AI
Future of Maternity Care - Pregnancy + AI In d iv id u a l Pre g n a n c y AI / LLM Im p ro v e d c a re t h ro u g h Da t a Co lle c t e d Da t a a n a ly s is p re d ic t iv e m o d e ls For personal use only • Predictive Risk Admin, Demographics mapping • Identification of high Vital Signs (Weigh
Slide 24: ESG Leadership
ESG Leadership Leveraged To Participate In Long-Term Structural ESG Trends HeraMED - Key ESG Initiatives For personal use only and Achievements #1 Ukraine Supporting mothers at war using remote patient monitoring #2 Rozana Building bridges between Israeli & Palestinian through health #3 Ethiopia & N
Slide 25: Recent Achievements & Upcoming Milestones
Recent Achievements & Upcoming Milestones Change of Leadership & Strategic Review US: Launch of Strategic four-point plan • Broward health; o Scale up mothers on HeraCARE For personal use only Over $7m in new capital raised o Complete EPIC integration with over 12 months runway o Finalise reim
Slide 26: HeraMED Limited
HeraMED Limited (ASX:HMD) For personal use only Anoushka Gungadin Managing Director & CEO E: anoushka@hera-med.com M:+61 431 131 649 Tim Chapman Chairman E: tchapman@claritycap.com.au M: +61 419 897 062 Matthew Wright Investor/Media Relations E: matt@nwrcommunications.com.au M: +61 451 896 420 26
Slide 27: Board of Directors, Leadership Team and Advisory Board
Bo a rd o f Dire c t o rs For personal use only Tim Chapman Anoushka Gungadin David Hinton Chairman Managing Director Non-Executive Director Le a d e rs h ip t e a m Anoushka Gungadin Cameron Jones Nicole Zappala Dr. Arturo Weschler Moran Shochat Ariel Laden Chief Executive Officer Chief Financial O
Slide 28: HeraCARE Competitive Advantage
HeraCARE Competitive Advantage Market leading technology, functionality and customer interface FEATURES HeraMED NUVO Babyscripts For personal use only FDA-cleared Fetal HR - Fetal HR as early as 16 weeks gestation Starting 32 weeks - Fetal monitor technology Ultrasound Doppler Fetal ECG - Continuous